SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 49.77 USD -2.18% Market Closed
Market Cap: 3.7B USD

EV/EBITDA
Enterprise Value to EBITDA

-12.4
Current
-6.5
Median
3.9
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-12.4
=
Enterprise Value
3.4B USD
/
EBITDA
-274.7m USD
EBITDA Growth EV/EBITDA to Growth
US
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Average EV/EBITDA: 58
Negative Multiple: -12.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 888.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
NL
argenx SE
XBRU:ARGX
306.7
168%
1.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-21.1
2-Years Forward
EV/EBITDA
-26
3-Years Forward
EV/EBITDA
N/A